NCT06956144

Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 113 (estimated)
• Sponsor: The First Affiliated Hospital of Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Accepted

Summary

To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

Detailed description

Images will be analyzed by at least two physicians with extensive experience in nuclear medicine and radiological diagnostics. Regions of interest (ROIs) will be delineated for the lesion tissues to measure volume and SUV values. The interpreted PET/CT imaging results will be compared to the corresponding histopathological results of the lesions (obtained through biopsy or surgery) and will be used as the reference standard. We will employ McNemar's test to compare the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of targeted CAIX PET/CT imaging and enhanced CT in primary tumors, metastatic lymph nodes, and distant metastatic lesions.

Conditions

• Tumor
• Carbonic Anhydrase IX

Timeline

• Start date: 2025-05-09
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-05-02
• Last updated: 2025-05-29

Locations

1 site across 1 country: China